IL196998A0 - Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders - Google Patents

Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders

Info

Publication number
IL196998A0
IL196998A0 IL196998A IL19699809A IL196998A0 IL 196998 A0 IL196998 A0 IL 196998A0 IL 196998 A IL196998 A IL 196998A IL 19699809 A IL19699809 A IL 19699809A IL 196998 A0 IL196998 A0 IL 196998A0
Authority
IL
Israel
Prior art keywords
treatment
proliferative disorders
pyrimidine derivatives
derivatives useful
morpholino pyrimidine
Prior art date
Application number
IL196998A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Finlay Maurice Raymond Verscho
Pike Kurt Gordon
Morris Jeffrey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38720451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL196998(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0616747A external-priority patent/GB0616747D0/en
Application filed by Astrazeneca Ab, Finlay Maurice Raymond Verscho, Pike Kurt Gordon, Morris Jeffrey filed Critical Astrazeneca Ab
Publication of IL196998A0 publication Critical patent/IL196998A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL196998A 2006-08-24 2009-02-11 Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders IL196998A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0616747A GB0616747D0 (en) 2006-08-24 2006-08-24 Novel compounds
US94854407P 2007-07-09 2007-07-09
PCT/GB2007/003173 WO2008023159A1 (en) 2006-08-24 2007-08-21 Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders

Publications (1)

Publication Number Publication Date
IL196998A0 true IL196998A0 (en) 2009-11-18

Family

ID=38720451

Family Applications (1)

Application Number Title Priority Date Filing Date
IL196998A IL196998A0 (en) 2006-08-24 2009-02-11 Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders

Country Status (15)

Country Link
US (1) US7750003B2 (index.php)
EP (1) EP2057140B1 (index.php)
JP (1) JP5534811B2 (index.php)
KR (1) KR101435231B1 (index.php)
AR (1) AR062526A1 (index.php)
AU (1) AU2007287428B2 (index.php)
CA (1) CA2660758A1 (index.php)
CL (1) CL2007002446A1 (index.php)
CO (1) CO6150160A2 (index.php)
IL (1) IL196998A0 (index.php)
MX (1) MX2009002046A (index.php)
NO (1) NO20090631L (index.php)
PE (1) PE20081362A1 (index.php)
UY (1) UY30559A1 (index.php)
WO (1) WO2008023159A1 (index.php)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4903164A (en) 1988-12-08 1990-02-20 Texas Instruments Incorporated O-ring/back-up ring seal for high pressure transducers
EP1693804B1 (en) * 1996-09-04 2009-11-11 Intertrust Technologies Corp. Trusted infrastructure support systems, methods and techniques for secure electronic commerce, electronic transactions, commerce process control and automation, distributed computing and rights management
WO2008014199A2 (en) 2006-07-28 2008-01-31 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the cb2 receptor
AU2007287428B2 (en) 2006-08-24 2011-08-11 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
CA2664310A1 (en) 2006-09-25 2008-04-03 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
WO2008086014A2 (en) * 2007-01-09 2008-07-17 Amgen Inc. Bis-aryl amide derivatives useful for the treatment of cancer
CN101711241A (zh) * 2007-02-06 2010-05-19 诺瓦提斯公司 Pi3-激酶抑制剂和它们的使用方法
EP2176238B1 (en) * 2007-07-09 2012-04-18 AstraZeneca AB Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k
WO2009007748A2 (en) * 2007-07-09 2009-01-15 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
JP5492092B2 (ja) 2007-11-07 2014-05-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節する化合物
WO2009094224A1 (en) 2008-01-25 2009-07-30 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
CN101981003B (zh) 2008-02-29 2014-07-02 伊沃泰克股份公司 酰胺化合物、组合物及其应用
JP2011520884A (ja) * 2008-05-13 2011-07-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を変調するスルホン化合物
RS55960B1 (sr) 2008-05-23 2017-09-29 Wyeth Llc Triazinska jedinjenja kao inhibitori pi3 kinaze i mtor
JP5596026B2 (ja) 2008-06-19 2014-09-24 ミレニアム ファーマシューティカルズ， インコーポレイテッド チオフェン又はチアゾール誘導体及びｐｉ３ｋ阻害剤としてのそれらの使用
EP2326629B1 (en) 2008-07-10 2013-10-02 Boehringer Ingelheim International GmbH Sulfone compounds which modulate the cb2 receptor
CA2729045A1 (en) 2008-07-31 2010-02-04 Philippe Bergeron Pyrimidine compounds, compositions and methods of use
US20110166135A1 (en) 2008-09-10 2011-07-07 Hiroshi Morimoto Aromatic nitrogen-containing 6-membered ring compounds and their use
EP2346825A2 (en) 2008-09-18 2011-07-27 Evotec AG Modulators of p2x3 receptor activity
AU2009296837A1 (en) 2008-09-25 2010-04-01 Boehringer Ingelheim International Gmbh Sulfonyl compounds which selectively modulate the CB2 receptor
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
TW201028410A (en) 2008-12-22 2010-08-01 Astrazeneca Ab Chemical compounds 610
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CN102395585A (zh) 2009-01-30 2012-03-28 米伦纽姆医药公司 杂芳基化合物和其作为pi3k抑制剂的用途
ES2529205T3 (es) 2009-03-13 2015-02-17 Cellzome Limited Derivados de pirimidina como inhibidores de mTOR
WO2010120991A1 (en) * 2009-04-17 2010-10-21 Wyeth Llc 5, 6, 7, 8-tetrahydropyrido[4,3-d]pyrimidine compounds, their use as mtor, pi3, and hsmg-1 kinase inhibitors, and their syntheses
US8835429B2 (en) * 2009-04-17 2014-09-16 Wyeth Llc Pyrimidine compounds, their use as mTOR kinase and Pl3 kinase inhibitors, and their syntheses
WO2010120996A1 (en) * 2009-04-17 2010-10-21 Wyeth Llc 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
US20120071475A1 (en) * 2009-04-27 2012-03-22 Shionogi & Co., Ltd. Urea derivatives having pi3k-inhibiting activity
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
JP5756800B2 (ja) 2009-06-16 2015-07-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節するアゼチジン２−カルボキサミド誘導体
UY32717A (es) 2009-06-17 2011-01-31 Vertex Pharma Inhibidores de la replicación de virus de la gripe
CN102480961A (zh) * 2009-06-24 2012-05-30 健泰科生物技术公司 与含氧杂环稠合的嘧啶化合物、组合物和使用方法
JP2013505295A (ja) 2009-09-22 2013-02-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を選択的に調節する化合物
AU2010313152A1 (en) 2009-10-30 2012-04-19 Ariad Pharmaceuticals, Inc. Methods and compositions for treating cancer
CN102711766B (zh) 2009-11-12 2014-06-04 霍夫曼-拉罗奇有限公司 N-9-取代的嘌呤化合物、组合物和使用方法
CA2780018C (en) 2009-11-12 2015-10-20 F. Hoffmann-La Roche Ag N-7 substituted purine and pyrazolopyrimidine compounds, compositions and methods of use
US9315491B2 (en) 2009-12-28 2016-04-19 Development Center For Biotechnology Pyrimidine compounds as mTOR and PI3K inhibitors
EP2523936A1 (en) 2010-01-15 2012-11-21 Boehringer Ingelheim International GmbH Compounds which modulate the cb2 receptor
US9249129B2 (en) 2010-03-04 2016-02-02 Cellzome Limited Morpholino substituted urea derivatives as mTOR inhibitors
EP2542539B1 (en) 2010-03-05 2014-02-26 Boehringer Ingelheim International GmbH Tetrazole compounds which selectively modulate the cb2 receptor
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
WO2012012307A1 (en) 2010-07-22 2012-01-26 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the cb2 rece
US8859768B2 (en) 2010-08-11 2014-10-14 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
TW201217365A (en) 2010-08-11 2012-05-01 Millennium Pharm Inc Heteroaryls and uses thereof
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2012044727A2 (en) 2010-10-01 2012-04-05 Novartis Ag Manufacturing process for pyrimidine derivatives
JP2013542941A (ja) 2010-10-13 2013-11-28 ミレニアム ファーマシューティカルズ， インコーポレイテッド ヘテロアリールおよびその使用
US8440662B2 (en) 2010-10-31 2013-05-14 Endo Pharmaceuticals, Inc. Substituted quinazoline and pyrido-pyrimidine derivatives
WO2012136622A1 (en) 2011-04-04 2012-10-11 Cellzome Limited Dihydropyrrolo pyrimidine derivatives as mtor inhibitors
CN102887867B (zh) * 2011-07-21 2015-04-15 中国科学院上海药物研究所 一类三嗪类化合物、该化合物的制备方法及其用途
CN103842357A (zh) * 2011-07-26 2014-06-04 格吕伦塔尔有限公司 作为类香草素受体配体的被取代的、含有杂芳环吡唑的羧酰胺和脲衍生物
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
DK2753606T3 (en) * 2011-09-02 2017-10-02 Purdue Pharma Lp PYRIMIDINES AS SODIUM CHANNEL BLOCKERS
WO2013041652A1 (en) 2011-09-21 2013-03-28 Cellzome Limited Morpholino substituted urea or carbamate derivatives as mtor inhibitors
US9242993B2 (en) 2011-10-07 2016-01-26 Cellzome Limited Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mTOR inhibitors
KR20160027217A (ko) 2012-05-23 2016-03-09 에프. 호프만-라 로슈 아게 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
US9296727B2 (en) 2013-10-07 2016-03-29 Vertex Pharmaceuticals Incorporated Methods of regioselective synthesis of 2,4-disubstituted pyrimidines
AU2014348752C1 (en) 2013-11-13 2019-11-21 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
SG10201804026WA (en) 2013-11-13 2018-06-28 Vertex Pharma Inhibitors of influenza viruses replication
BR112016027133A8 (pt) * 2014-05-21 2021-06-29 Allergan Inc derivados de imidazol como moduladores do receptor de formil peptídeo, composição farmacêutica e uso
MY194204A (en) 2014-08-04 2022-11-21 Nuevolution As Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
MA42422A (fr) 2015-05-13 2018-05-23 Vertex Pharma Inhibiteurs de la réplication des virus de la grippe
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
EP3630116B1 (en) 2017-05-26 2024-05-01 The Board Of Regents Of The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase
HUE066043T2 (hu) 2017-07-13 2024-07-28 Univ Texas A TR kináz beterociklusos inhibitorai
EP3668839B1 (en) 2017-08-17 2023-04-12 Board of Regents, The University of Texas System Heterocyclic inhibitors of atr kinase
EP3765008B1 (en) 2018-03-16 2023-06-07 Board of Regents, The University of Texas System Heterocyclic inhibitors of atr kinase
CN112047938B (zh) 2019-06-06 2022-11-22 北京泰德制药股份有限公司 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
WO2021124277A1 (en) 2019-12-20 2021-06-24 Nuevolution A/S Compounds active towards nuclear receptors
US11685727B2 (en) 2019-12-20 2023-06-27 Nuevolution A/S Compounds active towards nuclear receptors
AU2021245397A1 (en) 2020-03-31 2022-10-20 Nuevolution A/S Compounds active towards nuclear receptors
CA3174176A1 (en) 2020-03-31 2021-10-07 Sanne Schroder Glad Compounds active towards nuclear receptors

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3922735A1 (de) 1989-07-11 1991-01-24 Hoechst Ag Aminopyrimidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide
JP3810017B2 (ja) * 2000-04-27 2006-08-16 アステラス製薬株式会社 縮合ヘテロアリール誘導体
CA2407593C (en) * 2000-04-27 2011-01-11 Yamanouchi Pharmaceutical Co. Ltd. Fused heteroaryl derivatives
DK1335906T3 (da) * 2000-11-10 2007-02-05 Hoffmann La Roche Pyrimidinderivater og anvendelse deraf som neuropeptid Y-receptorligander
AU2003295776B2 (en) * 2002-11-21 2011-05-12 Novartis Vaccines And Diagnostics, Inc. 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer
EP1626725A4 (en) 2003-05-29 2006-06-14 Synta Pharmaceuticals Corp Heterocyclic compounds for the prevention and treatment of disorders associated with excessive bone formation
GB0415367D0 (en) * 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415365D0 (en) * 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415364D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
WO2007084413A2 (en) 2004-07-14 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP2008519850A (ja) * 2004-11-10 2008-06-12 シンタ ファーマシューティカルズ コーポレーション Ｉｌ−１２調節化合物
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
US7863270B2 (en) * 2005-05-13 2011-01-04 Synta Pharmaceuticals Corp. IL-12 modulatory compounds
ES2473341T3 (es) 2005-05-20 2014-07-04 Methylgene Inc Inhibidores de la se�alizaci�n del receptor del VEGF y del receptor del HGF
DE102005024494A1 (de) * 2005-05-27 2006-11-30 Bayer Healthcare Ag Verwendung von Cyanopyrimidinen
KR20080015475A (ko) 2005-07-01 2008-02-19 아이알엠 엘엘씨 단백질 키나제 억제제로서의 피리미딘-치환 벤즈이미다졸유도체
WO2007013691A1 (ja) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited スピロ環化合物
WO2007027855A2 (en) 2005-09-01 2007-03-08 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
JP2007091649A (ja) 2005-09-29 2007-04-12 Taisho Pharmaceut Co Ltd ピリミジン誘導体及びその使用に関連する治療方法
JP4531027B2 (ja) 2005-09-29 2010-08-25 田辺三菱製薬株式会社 医薬組成物
NZ567133A (en) 2005-09-30 2011-07-29 Vertex Pharma Deazapurines useful as inhibitors of janus kinases
CA2622352C (en) 2005-09-30 2014-05-27 Miikana Therapeutics, Inc. Substituted pyrazole compounds
GB0520657D0 (en) * 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
GB2431156A (en) 2005-10-11 2007-04-18 Piramed Ltd 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
WO2007049041A1 (en) 2005-10-28 2007-05-03 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
US20100016319A1 (en) 2005-11-29 2010-01-21 Toray Industries, Inc. A Corporation Of Japan Arylmethylene urea derivative and use thereof
GB0525083D0 (en) 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
GB0525080D0 (en) 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
GB0525081D0 (en) 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
BRPI0706395A2 (pt) 2006-01-11 2011-03-22 Astrazeneca Ab composto, uso do mesmo, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente e para tratar doença, composição farmacêutica, e, processo para preparar um composto
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
BRPI0706747A2 (pt) 2006-01-30 2011-04-05 Exelixis Inc 4-aril-2-amino-pirimidinas ou 4-aril-2-aminoalquil-pirimidinas como moduladores jak-2 e composições farmacêuticas que os contenham
EP2008210A1 (en) 2006-03-15 2008-12-31 Csir Modulation of phosphoryl transferase activity of glutamine synthetase
JP5243696B2 (ja) 2006-03-17 2013-07-24 田辺三菱製薬株式会社 ベンゼン誘導体
EP2003131A4 (en) 2006-04-04 2009-12-16 Taisho Pharmaceutical Co Ltd AMINOPYRROLIDINE COMPOUND
WO2007124288A1 (en) 2006-04-19 2007-11-01 Novartis Ag Indazole compounds and methods for inhibition of cdc7
WO2007126043A1 (ja) 2006-04-27 2007-11-08 Mitsubishi Tanabe Pharma Corporation チアゾール環を含むカルボン酸誘導体の医薬用途
GB0610909D0 (en) 2006-06-05 2006-07-12 Merck Sharp & Dohme Therapeutic treatment
AU2007269540B2 (en) 2006-07-05 2013-06-27 Exelixis, Inc. Methods of using IGF1R and Abl kinase modulators
AU2007287428B2 (en) 2006-08-24 2011-08-11 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
EP2057129A1 (en) 2006-08-24 2009-05-13 AstraZeneca AB Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
CA2683619A1 (en) 2007-04-12 2008-10-23 F. Hoffmann-La Roche Ag Pharmaceutical compounds

Also Published As

Publication number Publication date
US20080171743A1 (en) 2008-07-17
EP2057140A1 (en) 2009-05-13
CO6150160A2 (es) 2010-04-20
EP2057140B1 (en) 2012-08-08
JP5534811B2 (ja) 2014-07-02
CL2007002446A1 (es) 2008-04-04
PE20081362A1 (es) 2008-11-14
KR101435231B1 (ko) 2014-10-02
NO20090631L (no) 2009-03-16
AR062526A1 (es) 2008-11-12
KR20090053928A (ko) 2009-05-28
AU2007287428A1 (en) 2008-02-28
AU2007287428B2 (en) 2011-08-11
UY30559A1 (es) 2008-03-31
JP2010501534A (ja) 2010-01-21
MX2009002046A (es) 2009-03-06
US7750003B2 (en) 2010-07-06
HK1130776A1 (en) 2010-01-08
CA2660758A1 (en) 2008-02-27
WO2008023159A1 (en) 2008-02-28

Similar Documents

Publication Publication Date Title
IL196998A0 (en) Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
IL195731A0 (en) Pyrimidine derivatives useful in the treatment of cancer
IL195152A (en) Compounds for use in treating diseases of cell culture
IL192281A0 (en) Morpholino pyrimidine derivatives and their use in therapy
IL195906A0 (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
ZA201000106B (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
ZA201000087B (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
IL188390A0 (en) Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
ZA200901593B (en) Pyrimidines derivatives and their use as kinase inhibitors
IL179508A0 (en) 2-substituted-4- heteroaryl-pyrimidines useful for the treatment of proliferative disorders
IL205108A0 (en) Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
EP1853539A4 (en) HONOKIOL DERIVATIVES TO TREAT PROLIFERATIVE DISEASES
EP2063896A4 (en) KINASEHEMMER FOR THE TREATMENT OF PROLIFERATIVE DISEASES
IL186939A0 (en) Pyrimidine derivatives and their use as
ZA200708591B (en) Pyrimidine derivatives for treatment of hyperproliferative disorders
ZA201001264B (en) 1-amino-alkylcycohxane derivatives for the treatment of cochleat tinnitus
HUE037109T2 (hu) Endoxifén rák kezelésében történõ alkalmazásra
IL195900A0 (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
IL205578A0 (en) Aldh-2 inhibitors in the treatment of psychiatric disorders
ZA200901015B (en) Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
IL206107A0 (en) Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders
EP1951681A4 (en) NEW 2-AMINOPYRIMIDINE DERIVATIVES AND THEIR USE
ZA200902730B (en) Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer
IL209417A0 (en) 1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders
EP2099444A4 (en) USE OF D-SERIN DERIVATIVES FOR THE TREATMENT OF ANTIBODIES